$TRDA News

Entrada Therapeutics, Inc. (TRDA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Guggenheim Maintains Buy on Entrada Therapeutics, Lowers Price Target to $17

Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study

Entrada Advances Duchenne Muscular Dystrophy Drug to Higher Dose Cohort, Safety Review Clears Next Stage of Clinical Trial

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Entrada Therapeutics, Inc. (TRDA) Q1 2026 Earnings Call Transcript

Entrada’s stock drops as DMD drug’s efficacy falls short

HC Wainwright & Co. Downgrades Entrada Therapeutics to Neutral

Entrada Therapeutics Clinical Trial Data Sparks Brutal Stock Selloff - Here's Why

Entrada Therapeutics (NASDAQ:TRDA) Plunges Nearly 48% as Early-Stage DMD Clinical Data Disappoints on Drug Exposure

Entrada shares dive as Duchenne results disappoint

Entrada Therapeutics Reports First Quarter 2026 Financial Results

Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study

Entrada Therapeutics Q1 EPS $(0.95) Beats $(1.09) Estimate, Sales $875.000K Miss $1.393M Estimate

Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026

Oppenheimer Maintains Outperform on Entrada Therapeutics, Raises Price Target to $23

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

Earnings Summary: Entrada Therapeutics Q4

Entrada Therapeutics Q4 EPS $(0.94) Beats $(1.07) Estimate, Sales $1.299M Miss $13.886M Estimate